Your browser doesn't support javascript.
loading
Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis.
Oliinyk, Dmytro; Augustin, Teresa; Koehler, Viktoria Florentine; Rauch, Josefine; Belka, Claus; Spitzweg, Christine; Käsmann, Lukas.
Afiliação
  • Oliinyk D; Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Augustin T; Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Koehler VF; Department of Internal Medicine IV, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Rauch J; Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Belka C; Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Spitzweg C; German Cancer Consortium (DKTK), Partner Site Munich, 80336 Munich, Germany.
  • Käsmann L; Department of Internal Medicine IV, University Hospital, LMU Munich, 81377 Munich, Germany.
Cancers (Basel) ; 12(9)2020 Sep 03.
Article em En | MEDLINE | ID: mdl-32899355
ABSTRACT
Anaplastic thyroid carcinoma (ATC) is associated with a poor prognosis due to aggressive tumor growth and high treatment resistance. Hypofractionated treatment concepts may be more effective and less time consuming compared to normofractionated radiotherapy (RT). In this retrospective study, we aim to evaluate the outcome of hypofractionated regimens and perform a systematic review concerning hypofractionated RT and pooled analysis of this treatment modality. A systematic review using the MEDLINE/Pubmed and Cochrane databases was performed. Data from all eligible studies were extracted, and a pooled analysis of literature and our cohort (n = 60) was carried out to examine patient characteristics, toxicity, and outcomes of patients with ATC. As a result, median overall survival (OS) of the single center cohort was four (range 1-12) months. Survival rates at one, three, and six months were 82%, 55%, and 36%, respectively. In univariate analyses, multimodal treatment (p = 0.006) and gender (p = 0.04) were correlated with an improved OS. Six studies with a total number of 152 patients undergoing hypofractionated RT treatment were analyzed. The pooled analysis included four patient cohorts with 60 patients and showed median OS of 5.3 (range 1-24) months. Multimodal treatment (p < 0.001) and a cumulative radiation dose ≥50 Gy in equivalent dose in 2 Gy fractions (EQD2) (p = 0.014) correlated with an improved OS. On multivariate analysis, multimodal treatment (p = 0.003, hazard ratio (HR) 0.636, 95% confidence interval (CI) 0.469-0.861) was an independent predictor for longer OS. After propensity score matching (PSM), hypofractionated RT appears to be non-inferior compared to normofractionated RT concerning OS. In conclusion, hypofractionated RT is effective with manageable toxicity. A dose escalation with ≥50 Gy (EQD2) correlated with a longer OS. Hypofractionated RT could be an integral part in multimodal treatment with a promising outcome.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2020 Tipo de documento: Article